ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
64,979.51
0.59%
S&P 500
5,446.68
-1.37%
Dow Jones
40,347.97
-1.21%
US Dollar vs Yen
149.141
-0.41%
Brent Oil
79.97
-1.89%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) ニュース

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NBIX
日付受信時刻ニュースソース見出しコード企業名
2024/08/0123 : 51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0120 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0120 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0120 : 00PR Newswire (US)Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1906 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1906 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1905 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1905 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1905 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1821 : 30PR Newswire (US)Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1205 : 01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/0120 : 30PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAHNASDAQ:NBIXNeurocrine Biosciences Inc
2024/06/0505 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/06/0321 : 01PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
2024/06/0320 : 35PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
2024/06/0320 : 30PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/3105 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/3005 : 53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/3005 : 01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in JuneNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/2905 : 14PR Newswire (US)Neurocrine Biosciences Announces CEO Succession PlanNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/2821 : 30PR Newswire (US)Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/2407 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/2407 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/2407 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/05/2407 : 29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

最近閲覧した銘柄

NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
FX
USDEUR
US Dollar vs Euro
AMEX
XLF
Financial Select Sector
NASDAQ
MSFT
Microsoft
NYSE
AXP
American Express
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
NYSE
DIS
Walt Disney
AMEX
XLV
Health Care Select Sector
NYSE
NKE
Nike
NYSE
KO
Coca Cola
NYSE
BAC
Bank of America
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有